Literature DB >> 1497404

Cough and ACE inhibitors.

S R Simon1, H R Black, M Moser, W E Berland.   

Abstract

To assess the prevalence of cough as a side effect of angiotensin-converting enzyme inhibitor antihypertensive therapy, we reviewed 300 consecutive patient charts from a private practice and 200 consecutive patient charts from a university-based referral center for hypertension. Incidence of definite angiotensin-converting enzyme inhibitor-induced cough in the private practice was 25% and in the university practice, 7%, with an additional 6% of university-practice patients reporting a possible angiotensin-converting enzyme-inhibitor induced cough. This incidence is considerably greater than listed in the Physicians' Desk Reference. Reasons for the variability in incidence as reported in the literature are explored. Clinicians must be aware of this potentially disturbing side effect of angiotensin-converting enzyme inhibitors to avoid expensive and unnecessary diagnostic evaluations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1497404

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  18 in total

1.  ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in prescription-event monitoring.

Authors:  K Kubota; N Kubota; G L Pearce; W H Inman
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 2.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 3.  ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management.

Authors:  A Overlack
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 4.  Eprosartan: a review of its use in the management of hypertension.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 5.  Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges.

Authors:  Krishna Sriram; Rohit Loomba; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-17       Impact factor: 11.205

Review 6.  Appropriate use of antitussives and protussives. A practical review.

Authors:  R S Irwin; F J Curley; F M Bennett
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

7.  Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough.

Authors:  Takeshi Morimoto; Tejal K Gandhi; Julie M Fiskio; Andrew C Seger; Joseph W So; E Francis Cook; Tsuguya Fukui; David W Bates
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

Review 8.  Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.

Authors:  B Pitt; P Chang; P B Timmermans
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

Review 9.  Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.

Authors:  S Noble; E M Sorkin
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

10.  High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese.

Authors:  K S Woo; M G Nicholls
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.